Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 2/20 | 0.48 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | PRKACA | P17612 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | LOX | P28300 | 1/20 | 0.45 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.45 |
| ▸ | FEN1 | P39748 | 1/20 | 0.45 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12813082 | 0.96 | POLB (0.54) | POLBMAOAKDRNUDT1MAP4K4 | |
| SCHEMBL1892428 | 0.85 | MEN1 (0.50) | POLBMAOAKDRNUDT1ALOX5AP | |
| SCHEMBL31403749 | 0.82 | MAP4K4 (0.51) | KDRNUDT1MAP4K4NPC1RAB9A | |
| SCHEMBL11212136 | 0.80 | NUDT1 (0.57) | NUDT1AURKAHSP90AA1PRKACAADORA2A | |
| SCHEMBL1896504 | 0.80 | KDR (0.71) | KDRLOXL2LOX | |
| SCHEMBL31403557 | 0.79 | MAP4K4 (0.56) | POLBNUDT1MAP4K4HSP90AA1ALOX5AP | |
| SCHEMBL12813013 | 0.77 | ALDH1A1 (0.55) | KDRNUDT1ALDH1A1HTTTSHR | |
| SCHEMBL12812999 | 0.77 | MAP4K4 (0.56) | KDRMAP4K4LOXL2ALDH1A1 | |
| SCHEMBL4936375 | 0.76 | ROCK1 (0.54) | KDRRAB9AALDH1A1HTT | |
| SCHEMBL4272019 | 0.76 | ALDH1A1 (0.47) | MAP4K4LOXL2LOXBCAT2SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250161304-A1 | Methods for Treating Cancer Using Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity | MERCK PATENT GMBH (DE) | 2025-05-22 | — | — | US | disclosed |
| US-11491153-B2 | Methods for treating cancer using pyrimidine and pyridine compounds with BTK inhibitory activity | MERCK PATENT GMBH (DE) | 2022-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250161304-A1 | Methods for Treating Cancer Using Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity | BTK, SYK, LCK | POLB 1253/4885MAOA 2415/4885KDR 1059/4885 |
| US-11491153-B2 | Methods for treating cancer using pyrimidine and pyridine compounds with BTK inhibitory activity | BTK, SYK, LCK | POLB 1253/4885MAOA 2415/4885KDR 1059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.